AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$ORKA

Agarwal Arjun sold $51K of ORKA

Agarwal Arjun (Senior Vice President, Finance) sold 533 shares of Oruka Therapeutics, Inc. (ORKA) at $95.75 on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Agarwal Arjun
Published Sep 21, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Neutral
medium confidence
Mentioned
$ORKA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKANeutralLow
01

Why it matters

The disclosed sale is modest and likely part of a pre-arranged plan, offering limited trading insight.

02

Market read

Small insider sale with limited market impact.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 2/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$ORKANeutralMedium confidence
Context

Senior Vice President of Finance sold 533 shares for $51,034.75 via a 10b5-1 plan.

Expected impact

Minimal short-term impact; potential slight downward pressure.

Evidence & confidence

Sale amount is small relative to holdings and market cap; typical for 10b5-1 plans.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Negligible.

Counterpoint

What could challenge this read

Insider sale could be routine; no need to adjust position.

Key entities

  • Company
    Oruka Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker ORKA.

  • Insider
    Agarwal Arjun

    Senior Vice President, Finance at Oruka Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min